Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3118511 | 0.88 | SLC6A4 (0.43) | SLC6A3SLC6A4SLC6A2OPRM1CYP2D6 | |
| SCHEMBL3122249 | 0.88 | OPRM1 (0.52) | SLC6A3SLC6A4SLC6A2OPRM1CYP2D6 | |
| SCHEMBL3113113 | 0.86 | SLC6A4 (0.48) | SLC6A3SLC6A4SLC6A2OPRM1DRD4 | |
| SCHEMBL3120567 | 0.82 | SLC6A3 (0.42) | SLC6A3SLC6A4SLC6A2CYP2C19CYP3A4 | |
| SCHEMBL3122600 | 0.81 | CCR1 (0.46) | SLC6A3SLC6A4SLC6A2OPRM1DRD4 | |
| SCHEMBL17186726 | 0.77 | CCR1 (0.50) | SLC6A3SLC6A4SLC6A2OPRM1DRD4 | |
| SCHEMBL3123255 | 0.76 | SLC6A4 (0.43) | SLC6A3SLC6A4SLC6A2OPRM1KCNH2 | |
| SCHEMBL3115658 | 0.74 | SLC6A2 (0.36) | SLC6A3SLC6A4SLC6A2OPRM1DRD4 | |
| SCHEMBL3118374 | 0.74 | OPRM1 (0.38) | SLC6A3OPRM1CYP2C19CYP2C9DRD4 | |
| SCHEMBL16565154 | 0.73 | OPRM1 (0.48) | SLC6A3SLC6A4SLC6A2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155671-B1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2017-12-20 | — | — | EP | disclosed |
| US-8188301-B2 | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2012-05-29 | — | — | US | disclosed |
| US-20100179211-A1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB (DK) | 2010-07-15 | — | — | US | disclosed |
| EP-2155671-A2 | NEW DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008148801-A2 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL OF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179211-A1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | PNMT, DBH, SLC6A2 | SLC6A3 6/4885SLC6A4 17/4885SLC6A2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.